Latest posts tagged with #P53 on Bluesky
New paper from the lab out in Cell Death & Disease
@cddpress.bsky.social @cbm-csic-uam.bsky.social
"Transcription-dependent and -independent functions of Drosophila p53 isoforms in the induction of apoptosis and senescence-associated tumorigenesis.” #p53 #Drosophila Thread 1/9👇👇👇
El ciclo celular y sus particularidades 🔬
¡Nuevo vídeo corto en redes! ⬇️
Comentamos las diferentes fases del ciclo celular y las excepciones que hay.
#biología #divulgacióncientífica #células #ciencia #cienciaenespañol #interfase #mitosis #p53 #faseg0 #quiescencia #senescencia #divisióncelular
Mutant p53 & therapy response - weekly report 🧬
🔬 Highlight: TP53 mutations may predict poor response to taxane chemotherapy
TP53 status isn’t just biology, it’s clinical.
@biomednews.bsky.social
#p53 #CancerResearch #Oncology
biomed.news/bims-p53act/...
🧬 New report: Mutant p53 & cancer therapy
- TP53 CpG site mutations define an immune-activated tumor subtype and predict improved response to first-line chemoimmunotherapy in lung adenocarcinoma.
@biomednews.bsky.social
#p53 #CancerResearch #Immunotherapy
biomed.news/bims-p53act/...
Next up in the ZMB/@crc1430.bsky.social Speaker Series: Olaf Stemmann @unibayreuth.bsky.social on "The #p53 -dependent mitotic surveillance pathway: Insights into an anti-cancer cellular clock".
📅 24 March 2026
⏰ 4.15 pm
📍 S05 V01 E69
#genetics #cellbiology #mitosis
🧬 New report: Mutant p53 & anti-cancer therapy response
Highlights:
- TP53 loss links mTOR activation and immune-cold MSS colorectal cancer
- TP53 mutations associate with improved PFS with cetuximab+pembrolizumab in CRC
@biomednews.bsky.social
#p53 #CancerResearch
biomed.news/bims-p53act/...
Mutant #p53 doesn't just lose #tumor suppression: it actively drives replication stress and tumor growth. Targeting that vulnerability with Chk1 + ATM inhibitors could open the door to therapies for #cancers where p53 #mutations are extremely common like #lungcancer www.linkedin.com/posts/drmelv...
💊 Combining old and new: Actinomycin D + resveratrol shows enhanced #cancer cell killing in vitro via p53 activation—but in vivo, the combo doesn’t outperform the single agents. #CancerResearch #p53 #DrugSynergy
https://ow.ly/4zxx50Yh2co
🧬 New Mutant p53 research report!
Highlight:
- TP53-mut diffuse follicular lymphoma with cnLOH at 1p36 highlights molecular profiling.
- Mut p53 rewires CXCL10, boosting CD8⁺ T cells and anti-PD-1 response.
@biomednews.bsky.social
biomed.news/bims-p53act/...
#p53 #CancerResearch
People with Li Fraumeni syndrome (LFS) have mutations in a gene called TP53. Do you know the difference between P53 and TP53? We do use them interchangeably a lot. P53 refers to the protein that the gene TP53 makes.
#livinglfs #iamlivinglfs #p53 #tp53 #tp53gene #lfsawarenessmonth #lfsawarenessday
New Mutant p53 & Cancer Therapy Response Report is out! 🧬
Highlights:
• Lung-specific p53 mutants bind DNA but fail to transactivate
• Rezatapopt shows Phase I activity in Y220C tumors
@biomednews.bsky.social
#p53 #CancerResearch #Oncology
biomed.news/bims-p53act/...
Share if you love someone with LFS!
#lifraumeni #lifraumenisyndrome #livinglfs #iamlivinglfs #lifraumenisyndromeawareness #p53 #tp53 #tp53gene #cancergenetics #geneticcancer #geneticmutation #rarediseases #cancerfighter #rarediseaseday #lfsawareness #rarediseaseday2026
This latest phase I study in #NEJM of a first-in-class, ORAL! selective #p53 reactivator looks promising
Biomarkers that we were forced to study in med school are now potentially druggable!
www.nejm.org/doi/full/10....
New weekly Mutant p53 & Anti-Cancer Therapy Response report out now 🧬🧠
This issue highlights:
- Novel drug and prodrug candidates targeting TP53 mutations
- TP53-dependent cell fate in glioblastoma
@biomednews.bsky.social
biomed.news/bims-p53act/...
#p53 #Oncology #CancerResearch
👋Our February issue is out!
Cover: spatial #transcriptomics
👉Review: telomeric #chromatin
🔬 #mitochondria #mitophagy #senescence #p53 #epigenetics #glioblastoma #IDR #immunotherapy #cGASSTING #apoptosis #lysosomes & more!
www.nature.com/ncb/volumes/...
☕Yashinskie, Zhu et al show that #p53 activation triggers increased synthesis and accumulation of phospholipids, with enhanced activation of #autophagy and lysosomal catabolism programmes and increased reliance on lipid headgroup recycling. @lydiafinley.bsky.social
bit.ly/4asbwO3
New week, new report 🧬
My weekly Mutant p53 & anti-cancer therapy response report is out.
Fresh evidence on how TP53 mutations shape treatment response in cancer.
@biomednews.bsky.social
#p53 #Cancer #Oncology #CancerTherapy #BiomedsNews
biomed.news/bims-p53act/...
RESEARCH PAPER: Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer
By Shao et al., and Maureen Murphy
➡️ https://genesdev.cshlp.org/content/40/3-4/199.full
The Wistar Institute
#ovariancancer #p53 #cancertherapy #endocrineresistance
New in #AdvancedScience @wileylifesci.bsky.social
Cells can export the tumor suppressor #p53 in #exosomes and share it with neighbors. The transferred p53 remains functional—activating protective programs in recipient cells.
In this way cells might collaborate to prevent cancer.
📄 shorturl.at/veeKj
A new Biomeds News report is out 🚀
This week’s update on mutant p53 & anti-cancer therapy response - key papers, one place.
@biomednews.bsky.social
#p53 #CancerResearch #Oncology #BiomedsNews
biomed.news/bims-p53act/...
Mechanistic insights into how the CBLC-UBE2L6 axis promotes #OvarianCancer (OV) progression by driving the #Ubiquitination-dependent degradation of #p53, establishing CBLC as a tumor-promoting factor and a potential #TherapeuticTarget in OV.
#OpenAccess: doi.org/10.1016/j.ge...
Here we go again! Kicking off 2026 🚀, my weekly report about mutant p53 and anti-cancer therapy response is out.
@biomednews.bsky.social
#p53 #Oncology #CancerTherapy #BiomedsNews
biomed.news/bims-p53act/...
🆕 ADVANCE ONLINE 🆕
RESEARCH PAPER: Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer
By Shao et al., and Maureen Murphy The Wistar Institute
➡️ genesdev.cshlp.org/content/early/2025/11/05...
#ovariancancer #p53
#lifraumeni #lifraumenisyndrome #livinglfs #iamlivinglfs #lifraumenisyndromeawareness #p53 #tp53 #tp53gene #cancergenetics #geneticcancer #geneticmutation #rarediseases #cancerfighter
Thank you to Dr. Scott Lowe @mskcancercenter.bsky.social
for presenting #GrandRounds on potential programs to reveal and exploit the strategies nature uses to combat #cancer, including the impact of #p53 in #tumorsuppression.
Watch his full talk: youtube.com/watch?v=B6pj....
Thrilled to share our deconstruction of a p53 therapeutic response in #LUAD- a step toward drugging #undruggable #p53! Thanks to our amazing team and to Cancer Discovery @aacrjournals.bsky.social!
REVIEW: Mutant p53: evolving perspectives
By Gizem Efe, Katherine Cunningham, Anil K. Rustgi, Carol Prives, James J. Manfredi, and Francisco J. Sánchez-Rivera
➡️ https://genesdev.cshlp.org/content/40/1-2/43.full
#cancer #mutation #p53
Thinking of all our friends who know cancering doesn't take a break for the holidays 💙💚


#lifraumeni #lifraumenisyndrome #livinglfs #iamlivinglfs #lifraumenisyndromeawareness #p53 #tp53 #tp53gene #cancergenetics #geneticcancer #geneticmutation #rarediseases #cancerfighter
Just before Christmas🎄, my weekly Biomeds News report is out.
Growing evidence shows the clinical relevance of mutant p53 in treatment response, positioning it as a key axis in anticancer therapy.
@biomednews.bsky.social
#p53 #Oncology
biomed.news/bims-p53act/...
Merry Christmas!!!
🧬Mutant p53 & anticancer therapy - weekly update.
A curated snapshot of recent studies on therapy response, resistance and tumour adaptation across cancers.
biomed.news/bims-p53act/...
@biomednews.bsky.social
#p53 #Oncology #CancerResearch
